FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2419669872> ?p ?o ?g. }

• W2419669872 endingPage "1224" @default.
• W2419669872 startingPage "1214" @default.
• W2419669872 abstract "Rhabdomyosarcoma comprises two major subtypes, fusion positive (PAX3-FOXO1 or PAX7-FOXO1) and fusion negative. To investigate the significance of DNA methylation in these subtypes, we analyzed methylation profiles of 37 rhabdomyosarcoma tumors and 10 rhabdomyosarcoma cell lines, as well as 8 normal tissues. Unsupervised clustering of DNA methylation clearly distinguished the fusion-positive and fusion-negative subsets. The fusion-positive tumors showed substantially lower overall levels of methylation compared with fusion-negative tumors. Comparison with the methylation pattern of normal skeletal muscle and bone marrow indicates that fusion-negative rhabdomyosarcoma is more similar to these normal tissues compared with fusion-positive rhabdomyosarcoma, and suggests that many of the methylation differences between these subtypes arise from 'aberrant' hyper- and hypomethylation events in fusion-positive rhabdomyosarcoma. Integrative methylation and gene expression analysis revealed that methylation differences between fusion-positive and fusion-negative tumors could either be positively or negatively associated with mRNA expression. There was no significant difference in the distribution of PAX3-FOXO1-binding sites between genes with and without differential methylation. However, the finding that PAX3-FOXO1-binding sites were enriched among genes that were both differentially methylated and differentially expressed suggests that the fusion protein interacts with DNA methylation to regulate target gene expression. An 11-gene DNA methylation signature, classifying the rhabdomyosarcoma tumors into fusion-positive and fusion-negative subsets, was established and validated by pyrosequencing assays. Notably, EMILIN1 (part of the 11-gene signature) showed higher methylation and lower mRNA expression in fusion-positive compared with fusion-negative tumors, and demonstrated demethylation and re-expression in multiple fusion-positive cell lines after treatment with 5-aza-2'-deoxycytidine. In conclusion, our study demonstrates that fusion-positive and fusion-negative rhabdomyosarcoma tumors possess characteristic methylation profiles that contribute to the expression differences between these fusion subtypes. These findings indicate an important relationship between fusion status and epigenetic changes in rhabdomyosarcoma, present a novel approach for ascertaining fusion status, and may identify new therapeutic targets in rhabdomyosarcoma." @default.
• W2419669872 created "2016-06-24" @default.
• W2419669872 creator A5021862429 @default.
• W2419669872 creator A5023012274 @default.
• W2419669872 creator A5025441472 @default.
• W2419669872 creator A5026719110 @default.
• W2419669872 creator A5034181391 @default.
• W2419669872 creator A5036353718 @default.
• W2419669872 creator A5045440443 @default.
• W2419669872 date "2015-09-01" @default.
• W2419669872 modified "2023-10-16" @default.
• W2419669872 title "Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma" @default.
• W2419669872 cites W1504229479 @default.
• W2419669872 cites W1558871366 @default.
• W2419669872 cites W1964646880 @default.
• W2419669872 cites W1966917426 @default.
• W2419669872 cites W1998884405 @default.
• W2419669872 cites W2003670285 @default.
• W2419669872 cites W2008985082 @default.
• W2419669872 cites W2014945558 @default.
• W2419669872 cites W2017476119 @default.
• W2419669872 cites W2018310400 @default.
• W2419669872 cites W2034879676 @default.
• W2419669872 cites W2036350225 @default.
• W2419669872 cites W2055986128 @default.
• W2419669872 cites W2056040742 @default.
• W2419669872 cites W2060512760 @default.
• W2419669872 cites W2062972691 @default.
• W2419669872 cites W2065498897 @default.
• W2419669872 cites W2081182312 @default.
• W2419669872 cites W2081261283 @default.
• W2419669872 cites W2092687651 @default.
• W2419669872 cites W2095445212 @default.
• W2419669872 cites W2097360283 @default.
• W2419669872 cites W2101405991 @default.
• W2419669872 cites W2103077999 @default.
• W2419669872 cites W2107277218 @default.
• W2419669872 cites W2113950481 @default.
• W2419669872 cites W2119501563 @default.
• W2419669872 cites W2126510117 @default.
• W2419669872 cites W2126740719 @default.
• W2419669872 cites W2127736279 @default.
• W2419669872 cites W2137480884 @default.
• W2419669872 cites W2144048410 @default.
• W2419669872 cites W2146495496 @default.
• W2419669872 cites W2148708580 @default.
• W2419669872 cites W2150823666 @default.
• W2419669872 cites W2157795344 @default.
• W2419669872 cites W2166018507 @default.
• W2419669872 cites W2192080449 @default.
• W2419669872 cites W2416032761 @default.
• W2419669872 cites W4294107304 @default.
• W2419669872 cites W4294541781 @default.
• W2419669872 doi "https://doi.org/10.1038/modpathol.2015.82" @default.
• W2419669872 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6345526" @default.
• W2419669872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26226845" @default.
• W2419669872 hasPublicationYear "2015" @default.
• W2419669872 type Work @default.
• W2419669872 sameAs 2419669872 @default.
• W2419669872 citedByCount "35" @default.
• W2419669872 countsByYear W24196698722016 @default.
• W2419669872 countsByYear W24196698722017 @default.
• W2419669872 countsByYear W24196698722018 @default.
• W2419669872 countsByYear W24196698722019 @default.
• W2419669872 countsByYear W24196698722020 @default.
• W2419669872 countsByYear W24196698722021 @default.
• W2419669872 countsByYear W24196698722022 @default.
• W2419669872 countsByYear W24196698722023 @default.
• W2419669872 crossrefType "journal-article" @default.
• W2419669872 hasAuthorship W2419669872A5021862429 @default.
• W2419669872 hasAuthorship W2419669872A5023012274 @default.
• W2419669872 hasAuthorship W2419669872A5025441472 @default.
• W2419669872 hasAuthorship W2419669872A5026719110 @default.
• W2419669872 hasAuthorship W2419669872A5034181391 @default.
• W2419669872 hasAuthorship W2419669872A5036353718 @default.
• W2419669872 hasAuthorship W2419669872A5045440443 @default.
• W2419669872 hasBestOaLocation W24196698721 @default.
• W2419669872 hasConcept C104317684 @default.
• W2419669872 hasConcept C111829193 @default.
• W2419669872 hasConcept C123894998 @default.
• W2419669872 hasConcept C142724271 @default.
• W2419669872 hasConcept C150194340 @default.
• W2419669872 hasConcept C153911025 @default.
• W2419669872 hasConcept C190727270 @default.
• W2419669872 hasConcept C2778256501 @default.
• W2419669872 hasConcept C2780844630 @default.
• W2419669872 hasConcept C33288867 @default.
• W2419669872 hasConcept C40767141 @default.
• W2419669872 hasConcept C502942594 @default.
• W2419669872 hasConcept C54355233 @default.
• W2419669872 hasConcept C71924100 @default.
• W2419669872 hasConcept C86803240 @default.
• W2419669872 hasConceptScore W2419669872C104317684 @default.
• W2419669872 hasConceptScore W2419669872C111829193 @default.
• W2419669872 hasConceptScore W2419669872C123894998 @default.
• W2419669872 hasConceptScore W2419669872C142724271 @default.
• W2419669872 hasConceptScore W2419669872C150194340 @default.
• W2419669872 hasConceptScore W2419669872C153911025 @default.

• next